Astellas Pharma (OTCMKTS:ALPMY) Share Price Crosses Above Fifty Day Moving Average – Should You Sell?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $14.56 and traded as high as $16.35. Astellas Pharma shares last traded at $16.3150, with a volume of 78,171 shares trading hands.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Smbc Nikko Sec. raised shares of Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. Citigroup cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 19th. Four equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Astellas Pharma Price Performance

The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.84 and a current ratio of 1.09. The business has a 50 day moving average of $14.56 and a 200-day moving average of $12.59.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.15. The firm had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.21 billion. Astellas Pharma had a net margin of 15.63% and a return on equity of 23.62%. As a group, sell-side analysts expect that Astellas Pharma Inc. will post 0.42 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).